<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.immunetolerance.org" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>Immune Tolerance Network</title>
 <link>http://www.immunetolerance.org/professionals</link>
 <description>All news articles</description>
 <language>en</language>
<item>
 <title>Celebrate Ten Years of Tolerance!</title>
 <link>http://www.immunetolerance.org/news/2010/07/celebrate-ten-years-tolerance</link>
 <description>&lt;p&gt;
&lt;span style=&quot;font-family: &#039;Arial&#039;,&#039;sans-serif&#039;; color: black; font-size: 10pt&quot;&gt;This year marks the Immune Tolerance Network&amp;#39;s 10th anniversary! To celebrate, the ITN invites you to attend a one day symposium - &amp;quot;&lt;strong&gt;&lt;span style=&quot;font-family: &#039;Arial&#039;,&#039;sans-serif&#039;&quot;&gt;Ten Years of Tolerance&lt;/span&gt;&lt;/strong&gt;&amp;quot; on &lt;strong&gt;&lt;span style=&quot;font-family: &#039;Arial&#039;,&#039;sans-serif&#039;&quot;&gt;November 1, 2010&lt;/span&gt;&lt;/strong&gt; at the National Institutes of Health in Bethesda, MD.&lt;/span&gt; 
&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.immunetolerance.org/news/2010/07/celebrate-ten-years-tolerance&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.immunetolerance.org/category/news-type/general-news">General-News</category>
 <pubDate>Mon, 19 Jul 2010 12:54:59 -0700</pubDate>
 <dc:creator>ndarbous</dc:creator>
 <guid isPermaLink="false">641 at http://www.immunetolerance.org</guid>
</item>
<item>
 <title>Possible first new treatment for ANCA-associated vasculitis in 40 years</title>
 <link>http://www.immunetolerance.org/news/2010/07/possible-first-new-treatment-anca-associated-vasculitis-40-years</link>
 <description>&lt;p&gt;
Results of an Immune Tolerance Network clinical trial may provide doctors with another weapon in the treatment of ANCA-associated vasculitis, which has seen no new approved treatments in 40 years. The study, published in the New England Journal of Medicine, showed that the drug rituximab provides the same treatment benefits as the existing standard of care, and appears to offer additional benefits to those suffering relapses. 
&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.immunetolerance.org/news/2010/07/possible-first-new-treatment-anca-associated-vasculitis-40-years&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.immunetolerance.org/category/news-type/general-news">General-News</category>
 <pubDate>Thu, 15 Jul 2010 14:09:09 -0700</pubDate>
 <dc:creator>itn_admin</dc:creator>
 <guid isPermaLink="false">639 at http://www.immunetolerance.org</guid>
</item>
<item>
 <title>Kidney transplant tolerance “signatures” published in two separate JCI reports</title>
 <link>http://www.immunetolerance.org/news/2010/05/kidney-transplant-tolerance-%E2%80%9Csignature%E2%80%9D-published-two-separate-jci-reports</link>
 <description>The results of two Immune Tolerance Network (ITN)-sponsored efforts in identifying genetic and cellular signatures of transplant tolerance were published this week in the Journal of Clinical Investigation. The signatures are patterns of gene expression and cell types that were found to be characteristic of a set of rare patients who developed a natural tolerance for their kidney transplant – meaning they do not require anti-rejection medications.&lt;p&gt;&lt;a href=&quot;http://www.immunetolerance.org/news/2010/05/kidney-transplant-tolerance-%E2%80%9Csignature%E2%80%9D-published-two-separate-jci-reports&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.immunetolerance.org/category/news-type/general-news">General-News</category>
 <pubDate>Wed, 26 May 2010 14:15:19 -0700</pubDate>
 <dc:creator>itn_admin</dc:creator>
 <guid isPermaLink="false">621 at http://www.immunetolerance.org</guid>
</item>
<item>
 <title>Request for Proposals - Clinical Trials in Immune Tolerance</title>
 <link>http://www.immunetolerance.org/news/2010/04/request-proposals-clinical-trials-immune-tolerance</link>
 <description>The ITN is currently seeking Concept Proposals for novel clinical trials designed to induce immune tolerance in Type 1 Diabetes, transplantation, autoimmune diseases, and allergy and asthma.  In addition the ITN accepts applications for the development of novel tolerance assays or mechanistic studies for the purposes of establishing new surrogate biomarkers of immune tolerance and investigating the mechanisms of clinical tolerance.  Proposals should be submitted via our site:  &lt;a href=&quot;/professionals/proposals/guidelines&quot;&gt;http://www.immunetolerance.org/professionals/proposals/guidelines&lt;/a&gt;&lt;p&gt;&lt;a href=&quot;http://www.immunetolerance.org/news/2010/04/request-proposals-clinical-trials-immune-tolerance&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <category domain="http://www.immunetolerance.org/category/news-type/general-news">General-News</category>
 <enclosure url="http://www.immunetolerance.org/sites/files/RFP - Clinical Trials in Immune Tolerance.pdf" length="75662" type="application/pdf" />
 <pubDate>Mon, 26 Apr 2010 10:57:49 -0700</pubDate>
 <dc:creator>lstraub</dc:creator>
 <guid isPermaLink="false">617 at http://www.immunetolerance.org</guid>
</item>
</channel>
</rss>
